Treatment of severe persistant asthma with masitinib
US9078894B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2012 |
| Grant date | Jul 14, 2015 |
| Priority date | — |
| Expiry date | Feb 3, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the treatment of severe persistent asthma, and in particular severe persistent corticosteroid-dependent or corticosteroid-resistant asthma, comprising administration a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.